Amp Volatility Score
Catalyst Info & Data Links
TITLE: Vascepa Phase 2 clinical trial data
NCT04412018: An Investigation on the Effects of Icosapent Ethyl (VascepaTM) on Inflammatory Biomarkers in Individuals With COVID-19
WHAT IS THE CATALYST EVENT?
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
MECHANISM OF ACTION
Vacepa is a capsule containing Icosapent Ethyl. An Omega-3 fatty acid EPA approved for lowering TG levels in patients. Seeing how Vacepa helps with Cardiovascular complications, and up to 40% of deaths are related to CV complications, it stands to reason Vascepa could potentially be a therapy.
AMRN, Vascepa, COVID-19drug
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post